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a b s t r a c t
Early debridement and/or eschar removal is regarded as a significant step in the treatment of
deep partial and full thickness burns. It aims to control wound bioburden and allows early
wound closure by conservative treatment or skin grafting. Preservation of viable dermis
accompanied by early wound closure, is regarded as a necessary step to reduce scar related
complication, e.g. functional limitations and/or unaesthetic scar formation. Aside from the
classical techniques of surgical excision as tangential excision for eschar removal, hydro-
surgery, maggot therapy, laser, enzymatic debridement have been described as additional
techniques in the burn surgeon’s armamentarium. It is widely accepted that early eschar
removal within 72h improves the outcome of burn wound treatment by reducing bacterial
wound colonization, infection and length of hospital stay. In contrast, the right technique for
eschar removal is still a matter of debate. There is increasing evidence that enzymatic
debridement is a powerful tool to remove eschar in burn wounds, reducing blood loss, the
need for autologous skin grafting and the number of wounds requiring surgical excision. In
order to assess the role and clinical advantages of enzymatic debridement by a mixture of
proteolytic enzymes enriched in Bromelain (Nexobrid
1
) beyond the scope of the literature
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and in view of users’ experience, a European Consensus Meeting was scheduled. The aim was
to provide statements for application, based on the mutual experience of applying enzymatic
debridement in more than 500 adult and pediatric patients by the consensus panelists. Issues
to be addressed were: indications, pain management and anesthesia, timing of application,
technique of application, after-intervention care, skin grafting after enzymatic debridement,
blood loss, training strategies and learning curve and areas of future research needs. Sixty-
eight (68) consensus statements were provided for the use of enzymatic debridement. The
degree of consensus was remarkably high, with a unanimous consensus in 88.2% of
statements, and lowest degree of consensus of 70% in only 3 statements. This consensus
document may serve as preliminary guideline for the use of enzymatic debridement with
user-oriented recommendations until further evidence and systematic guidelines are
available.
© 2017 Elsevier Ltd and ISBI. All rights reserved.
1. Introduction
Early eschar removal is regarded as the key step in the
treatment of deep partial and full thickness burns. Xiao-Wu
et al. have demonstrated that early excision within 48h of
injury can significantly reduce the rate of invasive infection,
sepsis and length of hospital stay [1]. In accordance, Barret and
Herndon showed that a significant reduction of bacterial
colonization, bacterial counts and infection rate is possible by
early excision within 24h of injury compared to later excision
[2].
It is widely accepted that early eschar removal within 48h
may improve the outcome of burn wound treatment. Never-
theless, the complexity of burn depth assessment within this
time frame due to burn depth progression and late demarca-
tion, as well as logistical reasons sometimes postpone the ideal
time of eschar removal, which may lead to additional injury
and loss of viable dermis. In summary, the optimal technique
for eschar removal should selectively remove nonviable
burned tissue, achieve minimal blood loss, allow for optimal
clinical wound bed evaluation and treatment decisions
resulting in faster wound healing by means of conservative
treatment or early surgical coverage by autologous skin
grafting in order to improve aesthetic and functional outcome
and thus the quality of life.
The choice of the optimal technique is still a matter of
debate. Aside from the classical technique of surgical excision,
various other techniques have been developed, applied and
validated for burn eschar removal, providing a level of
evidence that ranges between 2 to 5: these techniques include
hydro-surgery, maggot therapy, laser, collagenase based
enzymatic gel treatment, special cautery systems and Brome-
lain based enzymatic debridement [3–14].
It has been reported that classical surgical excisions done
within the first 24h after burn injury may significantly reduce
blood loss during eschar removal [15]. The procedure itself is
regarded as a highly technical one, and a learning curve with
training is necessary [16]. Special knives for tangential excision
have to be fitted using varying thickness of skin guards to limit
the thickness of excised tissue, and presence of pinpoint
bleeding indicates the viable layer. Nevertheless, it is still
recommended to include a thin adjacent layer of viable tissue
into burn wound excision to enable safe transplant take and
total excision of the burn wound. For hydro-surgery (e.g.
Versajet
1
), there is evidence available that burn eschar
excision has the capacity to significantly reduce the amount
of excised viable dermis compared to standard of care, but
further superiority to tangential excision could not been
demonstrated so far [5–8]. In order to debride burn wounds
more superficially, Dessy et al. demonstrated that the use of
lubricants and a razor may reduce the pain during debride-
ment compared to the use of sterile gauze for scraping the roof
off, but no further superiority could be shown [17]. Fu et al.
compared collagenase based gel (Iruxol
1
mono) to Vaseline
treatment. They were able to show a reduction of necrotic
tissue after a minimum of 14 days of application of collagenase
gel in a randomized controlled trial (RCT) [12]. For the use of
medical maggots, larvae and cautery knife with air spray in
burn wound debridement only limited evidence is available
from case series predominantly showing feasibility of these
techniques without comparison to standard of care [3,13,14].
There is increasing evidence that enzymatic debridement is
a powerful tool to remove eschar in burn wounds, reducing
blood loss, the need for autologous skin grafting and the
number of wounds requiring surgical excision [4,11]. In
addition, it has been shown that enzymatic debridement
can reduce the rate of burn wound infection and the length of
hospital stay, which is mainly due to early application and
timely selective eschar removal [10].
In order to assess the role and advantages of Bromelain
based enzymatic debridement (Nexobrid
1
) beyond the scope
of the existing literature and in view of users' experience, a
European Consensus Meeting was scheduled to provide
statements for application.
2. Methods
European consensus guidelines on enzymatic debridement for
eschar removal in burns were formulated by a multistep
process, which included a systematic literature review (2000–
2016), expert panel discussion and voting on panel statements,
based on the only available approved drug Nexobrid
1
. Peer-
reviewed literature was used as a basis for pre-formulated
statements by the first and senior author (C.H. and U.K.). These
statements were the basis for panelist discussions. A formal
evaluation of the quality of the published evidence on
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enzymatic debridement was conducted applying the Oxford
Level of Evidence Classification System [18]. Due to the limited
number of publications and the novelty of the treatment
modality of enzymatic debridement in burns, systematic
consensus measures (e.g., Delphi method) were not applied,
and a modified consensus process was implemented.
2.1. Panelists
European expert panelists were selected by the first and senior
author (C.H. and U.K.) based on the following criteria: clinical
experience with the treatment regime of Enzymatic Debride-
ment, prior publications on the topic, expertise and reputation
in burn treatment, and role as key opinion leader. Selection of
panelists was limited to Europe due to the medical approval of
Nexobrid
1
. This included diversity of experience and practice
patterns of more than 500 summarized patient cases in
enzymatic debridement with Nexobrid
1
from a variety of
European geographic locations to provide a heterogeneous
expert panel sample. Panelists were selected from Austria,
Belgium, Germany, Italy, Slovak Republic, Spain, Switzerland
and United Kingdom and encompassed plastic surgeons and
burn surgeons. In order to serve the multi-professional aspects
of enzymatic debridement in burns, one non-physician
panelist (H.H.) also participated in the consensus meeting.
Every participating center had one vote per statement,
regardless of the number of participants present from the
center.
2.2. Process
Prior to the face-to-face meeting (which was scheduled in
January 2017 in Frankfurt, Germany), all panelists were
provided with 68 possible, pre-formulated consensus state-
ments on enzymatic debridement for eschar removal in burns
based on peer-reviewed publications and clinical relevance on
the following topics (10): indications, pain management and
anesthesia, timing of application, technique of application,
post-interventional wound management, skin grafting after
Enzymatic Debridement, blood loss, summary of cost-effec-
tiveness, training strategies and learning curve, areas of future
research needs.
The consensus workshop was divided into two major
sections:
The first section included the presentation of the system-
atic review on debridement and eschar removal in burns in
order to synchronize the level of evidence for the years 2000–
2016 in-between the panelists. The next major section
consisted of the re-presentation and discussion on major
issues of the clinical application of enzymatic debridement
based on 68 possible, pre-formulated consensus statements
followed by a final debate about which topics should be
included in the consensus guidelines. Consensus statements
were modified by the panelists during the discussion process.
Ten voting centers representing eight European countries
where enzymatic debridement is commonly used (Austria,
Belgium, Germany, Italy, Slovak Republic, Spain, Switzerland
and United Kingdom) were asked to mark agreement or
disagreement with each consensus statement at the end of the
debate.
All panelists were asked to reflect the consensus state-
ments list and results by proof-reading of the consensus
manuscript written and provided by C.H. and U.K. including a
follow-up discussion via email. Panelists were encouraged to
make comments and suggestions for changes to the manu-
script. The final version of the manuscript was accepted and
agreed for submission by all participants.
2.3. Consensus agreement
A systematic method for calculated consensus was not applied
due to the novelty of enzymatic debridement. The methodol-
ogy employed was an agreement algorithm based on a
modification of the Willy and Stellar method [19]. The
consensus model provided a classification scheme with cut-
offs for consensus agreement (Table 1), allowing to assess
degree of agreement for statement inclusion >50%.
The results of the consensus statements are provided in
tables based on the major topics (Table 2), with the first column
citing the consensus statement, followed distribution of “yes/
no” responses to the statement and the percentage of for
achieved consensus.
2.4. Standard of care
Throughout the whole consensus process, surgical excision
with tangential knives and/or hydro surgery were regarded as
surgical standard of care and if applicable compared to
enzymatic debridement. The panelists agreed that everything
that is not exclusively defined for enzymatic debridement,
shall follow the standard of care for burn eschar removal.
3. Results
Based on the consensus process, 68 statements were generat-
ed. These address clinical routine of enzymatic debridement
and include the experience of ten centers in eight European
Table 1 – Consensus ranking scheme, modified according to Willy and Stellar [19].
Rank Agreement % Agreement description
1 Strong consensus >95% or participants agree Statement should be included
2 Consensus >75–95% of participants agree Statement should be included
3 Majority approval >50–75% of participants agree Statement should be included
4 No consensus <50% of participants agree Statement should not be included
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nations with more than 500 cases treated. In addition,
statements were based on the available literature encompass-
ing the years 2000–2016. The consensus statements as basis for
the European Guidelines were sub-classified according to the
following topics: indications, pain management and anesthe-
sia, timing of application, technique of application, post-
interventional wound management, skin grafting after
enzymatic debridement, blood loss, summary of cost-effec-
tiveness, training strategies and learning curve, and areas of
future research needs.
In order to provide the published advantages of enzymatic
debridement in burn eschar removal to the patients and
experience successful and beneficial results of this technique,
users should obey the provided strong recommendations
during indication, treatment and further evaluation.
All consensus statements are listed in bold letters. In
addition, the results of the consensus are listed in brackets
after each statement. The following 68 statements are
summarized in Table 2.
Table 2 – Consensus statements on enzymatic debridement in burns. (For interpretation of the references to color in this table
legend, the reader is referred to the web version of this article.)
Stateme nt Yes/no reponses Cons ensu s
1. Ind icaons and  seng
Enzymac debridement should only be appli ed by 
experienced bu rn teams aer ad equa te training in 
enzymac debridement.  (10 /0) 100 %
Enzymac debridement wi th Nex obrid is a safe and  
reliab le alterna ve too l for early escha r removal in adu lts.   (10 /0) 100 %
Enzymac debridement may be appli ed in pediatric 
paents and is performed wi th sasfying results bu t this is 
curr ently considered as oﬀ lab el use.  (10 /0) 100 %
In case of a moist bu rn escha r, enzymac debridement
may be appli ed to all  bu rned surfaces.   (10 /0) 100 %
Enzymac debridement is ad van tageous in treatment 
for ha nds, fee t and face.  (10 /0) 100 %
Contact of enzymac debridement to the eyes and the 
tympa num  should be avoided.  (10 /0) 100 %
Enzymac debridement preserves viab le dermis more 
eﬃciently compa red to standard of care .  (10 /0) 100 %
Enzymac debridement as the only procedu re for 
debridement should be li mited to thermal bu rns, i.e. 
scald/ﬂame/contact bu rns.   (10 /0) 100 %
In add iona l trau ma, such as high voltage injury, blast 
injury or crush bu rn, surgical techn iqu es should be appli ed 
in order to release muscular compa rtment press ure and  
provide nerve decompress ion.  (10 /0) 100 %
Enzymac debridement cann ot be recomm end ed for 
escha r removal in chemical bu rns.   (10 /0) 100 %
Pretreatment wi th sil ver sulfad iazi ne or betad ine 
should be avoided.  (10 /0) 100 %
Standa rd bu rn wound  and  depth ass ess ment is 
suﬃcient prior to enzymac debridement.  (9/1) 90 %
Frequ ent ph otograph y and  wound  documentaon is 
strongly recomm end ed to provide wound  documentaon 
for all m embers of the bu rn team.  (9/1) 90 %
Enzymac debridement can  be regarded as a useful 
too l in case of li mited OR capa city.  (7/3) 70 %
Enzymac debridement can  be safely appli ed in up  to 
15% BSA in one sess ion (lab el). (10 /0) 100 %
Up to 30% BSA can  be treated by enzymac   
debridement ba sed on individual decision, bu t this is 
considered as oﬀ-label use. (10 /0) 100 %
Enzymac debridement can  be appli ed for early escha r 
removal in circumferenal ex tremity bu rns to prevent 
surgical escha rotomy as  standard of care but not to 
replace fasciotomy. (10 /0) 100 %
The ex tremity should be monitored and  surgical 
escha rotomy and/or fasciotomy should be performed if 
signs of deterioraon appear.  (10 /0) 100 %
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
(continued on next page)
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3.1. Indications and setting
3.1.1. Enzymatic debridement as an alternative tool compared
to standard of care
 Enzymatic debridement should only be applied by expe-
rienced burn teams after adequate training in ED. (10/10)
 Enzymatic debridement with Nexobrid is a safe and reliable
alternative tool for early eschar removal in adults. (10/10)
 Enzymatic debridement may be applied in pediatric
patients and is performed with satisfying results but this is
currently considered as off label use. (10/10)
Treatment of pediatric patients (age <18 years) is
formally considered as off-label use so far, which is the
major reason of the participants to be more restrictive in the
application. Treatment of pediatric patients should current-
ly be regarded a personal, clinical decision by the treating
physician. 5/10 centers have treated young pediatric pa-
tients, while 10/10 have treated children <18 years, mainly
adolescents >15 years of age. An approval study (https://
clinicaltrials.gov/ct2/show/NCT02278718) is open for inclu-
sion and is expected to provide further user relevant data on
the application of enzymatic debridement in pediatric
burns.
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 In case of a moist burn eschar, enzymatic debridement may
be applied to all burned surfaces. (10/10)
Enzymatic debridement advantages are most obvious in
burned surfaces, which have thin subcutaneous layers with
underlying functional structures and burned surfaces in which
surgical techniques (standard of care) are limited, and when
the risks of surgical burden and morbidity increase.
 Enzymatic debridement is advantageous in treatment for
hands, feet and face. (10/10)
 Contact of enzymatic debridement to the eyes and the
tympanic membrane should be avoided. (10/10)
For hands and face, enzymatic debridement is regarded to
be superior to hydro-surgery or standard of care which is also
reflected in the current literature [8,11,20,21]. Hydro-surgery is
limited to smaller areas due to the relatively small cutting unit.
Eyes should be carefully protected from the active agent by
local measures, which include Panthenol based ointment on
the cornea, stoma paste/vaseline and a dressing and tampo-
nade by e.g. fatty gauze in the ear.
Hands and feet, lower and upper extremity, are regions that
are ideal to start the learning curve with, due to the convenient
fixation of occlusive dressing to keep the active agent in place.
2/10 participants have experience in treating male and
female genitals and the perineum — locations which might
benefit from enzymatic debridement due to limitations of
standard of care in eschar removal in these regions, but there
are technical issues regarded as drawbacks in applying and
keeping the occlusive dressing on these areas during treat-
ment phase of enzymatic debridement.
3/10 participants have experience in treating the axillary
fold, where splints are helpful to keep the active agent in place.
3.1.2. Proposed role of enzymatic debridement for the
preservation of dermis
 Enzymatic debridement preserves viable dermis more
efficiently compared to standard of care. (10/10)
Enzymatic debridement is a powerful tool to selectively
remove burn eschar especially in mixed depth burn patterns,
where preservation of viable dermis and deeper layers is even
more challenging by standard of care.
3.1.3. Patient selection
The following statements aim to help the user identifying the
“ideal” patient and burn pattern to succeed in the treatment of
enzymatic debridement and minimize pitfalls.
3.1.3.1. Mechanism of burn: flame, electricity, chemical?.
 Enzymatic debridement as the only procedure for de-
bridement should be limited to thermal burns, i.e. scald/
flame/contact burns. (10/10)
 In additional trauma, such as high voltage injury, blast
injury or crush burn, surgical techniques should be applied
in order to release muscular compartment pressure and
provide nerve decompression. (10/10)
Enzymatic Debridement may be used in these cases for
debridement and subcutaneous pressure release, but it will
not release deeper compartment pressures. It might be used as
an additive procedure, when e.g. additional surface burns
without deep extent are present in high-voltage injury, blast
injury or crush injury.
 Enzymatic Debridement cannot be recommended for
eschar removal in chemical burns. (10/10)
2/10 centers have experience in the treatment of 5 chemical
burns, in which the power of early and selective eschar
removal by enzymatic debridement did not become evident.
As a consequence, due to limited evidence and unclear
demarcation of chemical burns, it cannot be recommended.
 Pretreatment with silver sulfadiazine or betadine should be
avoided. (10/10)
Based on the clinical trials and experience, pre-treatment
with silver sulfadiazine or betadine should be avoided if
possible. The suspected mechanism of interference with
Enzymatic Debridement efficacy is thought to be the thicker
layer on the eschar formed by these treatments or the heavy
metals. If pre-treatment with one of the above mentioned
agents is necessary due to in-house protocols and a lack of
availability of water-based gel alternatives, the contact time
should be kept as short as possible followed by sufficient
rinsing and (prolonged) pre-soaking.
3.1.3.2. Burn wound assessment. Burn wound assessment is
performed by clinical evaluation and can be followed by
technical measures, e.g. Laser Doppler Imaging (LDI) [22].
Regularly burn wound photography and IT based documenta-
tion provides improved comparability for optimal treatment
[23].
 Standard burn wound and depth assessment is sufficient
prior to enzymatic debridement. (9/10)
 Frequent photography and wound documentation is
strongly recommended to provide wound documentation
for all members of the burn team. (9/10)
Photography and decisive wound documentation during the
implementation of enzymatic debridement is strongly recom-
mended to shorten the learning curve for the whole burn team,
and to have the chance to discuss wound evaluation and
specific issues on enzymatic debridement and patterns.
The reasons for only a 9/10 consensus was the implemen-
tation of LDI as a standard diagnostic tool in one center where
it serves as a diagnostic tool in addition to clinical evaluation
before application of enzymatic debridement.
3.1.3.3. Role for mass casualty.
 Enzymatic debridement can be regarded as a useful tool in
case of limited OR capacity. (7/10)
A unanimous recommendation for the use of enzymatic
debridement in mass casualty events could not be reached (7/
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10) due to concerns of 3 panelists of creating a situation where
too many patients with open wounds requiring skin grafting
exist simultaneously; 1/10 centers reports advantages and
remarkable logistic and therapeutic opportunities in a mass
casualty event in 2016 where enzymatic debridement was
used on multiple patients.
3.1.4. Body surface
3.1.4.1. TBSA treated.
 Enzymatic debridement can be safely applied in up to 15%
BSA in one session. (10/10)
 Up to 30% BSA can be treated by enzymatic debridement
based on individual decision, but this is considered as off-
label use. (10/10)
6/10 participants have experience in treating up to 30% BSA
in one enzymatic debridement session, but application beyond
15% BSA per session is currently regarded as an off-label use.
Systemic aspects have to be considered in patients treated
with more that 15% BSA, mainly due to fluid loss, which has to
be recalculated in resuscitation fluids. Patients will require
additional fluids, invasive monitoring and pre-treatment risk
stratification.
Experience of the participants in treating >15% BSA ranges
up to 36% in one session, but it remains consensus that it
should not exceed 30% BSA per session.
3.1.4.2. Enzymatic debridement as a rapid tool for eschar removal
to prevent escharotomies in extremity burns. Surgical eschar-
otomies belong to the standard of care armamentarium in
burn surgery and provide emergent decompression of circum-
ferential eschar for the subcutaneous compartment and if
necessary for the deep muscular compartment. Early ED may
reduce the inflammation and edema formation and thus can
be regarded as a tool to prevent need for surgical escharot-
omies by relieving the pressure in the subcutaneous
compartment:
 Enzymatic debridement can be applied for early eschar
removal in circumferential extremity burns to prevent
surgical escharotomy as standard of care but not to replace
fasciotomy. (10/10)
 The extremity should be monitored and surgical eschar-
otomy and/or fasciotomy should be performed if signs of
deterioration appear. (10/10)
9/10 participants have experience in the treatment of
circumferential and near circumferential burns with eschar
removal by enzymatic debridement to prevent surgical
escharotomy. In case of suspected muscular compartment
syndrome, enzymatic debridement is not recommended as a
surgical fasciotomy is needed. 10/10 participants agree, that
early application of enzymatic debridement after the burn
trauma within the first hours is effective to prevent subcuta-
neous pressure increase, which may cause compartment
syndrome. The participants reported that there was no
incidence or necessity of conversion to surgical escharotomy
after early eschar removal by enzymatic debridement.
Compartment pressure must be assessed if enzymatic
debridement is applied in circumferential extremity burns
after thermomechanical trauma or high voltage injury in order
to assess the need of fasciotomy due to deep layer injuries.
3.2. Pain management and anesthesia
Enzymatic Debridement is regarded as a painful procedure and
requires analgesia or analgo-sedation/anesthesia depending
on the depth of burn and extent of BSA treated with enzymatic
debridement.
 Adequate pain management is essential before, during and
after Enzymatic Debridement. (10/10)
 Regional anesthesia is recommended for enzymatic de-
bridement at the isolated (upper) extremity. (7/10)
 Analgesics-based intravenous sedation or general anes-
thesia is recommended for enzymatic debridement at the
trunk and if different regions are treated at the same time.
(10/10)
Enzymatic debridement causes significant pain during
application and removal of the debris. For regional anesthesia,
long acting local anesthetic drugs (up to 8h) are recommended
(e.g. Ropivacaine). If not available, catheter based techniques
are necessary to provide long lasting anesthesia. Centers are
recommended to develop interdisciplinary pain management
concepts to implement the special aspects of enzymatic
debridement. In case of total extremity burn, it is recom-
mended to implement regional anesthesia through an
unburnt area in order to prevent infection (e.g. scalene muscle
level) or general anesthesia. Monitoring equipment is neces-
sary according to the type of anesthesia.
There is limited experience in performing enzymatic
debridement with local anesthesia (infiltration or tumes-
cence), which has been applied by 1/10 of the participating
centers. Some patients report of significant and prolonged
pain after intervention.
3.3. Timing of application
Timing of eschar removal is a key factor in burn care in general,
as it is with enzymatic debridement as well.
 Enzymatic debridement can be applied immediately after
initial assessment and wound preparation. (10/10)
 Later application (>72h from injury) is possible in selected
patients after appropriate preparation. (10/10)
Late application of enzymatic debridement benefits from
special preparation of the burned surface in order to reduce dry
surface and improve the effect of presoaking. This can be done
by surgical removal of superficial burn layers followed by
treatment and prolonged presoaking.
3.4. Application of Enzymatic Debridement
The technique of application is essential to achieve successful
eschar removal.
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3.4.1. Preparation of the wound
 Preparation of the wound by blister removal and superficial
debridement of keratin remnants is necessary prior to
treatment (before or after pre-soaking). (10/10)
3.4.2. Pre-soaking
 A moist wound environment is essential prior to enzymatic
debridement, because it does not work in dry wounds. (10/
10)
 A moist wound environment can be achieved by a pre-
soaking phase of at least 2h in acute burns <72h from
injury. (9/10)
 Pre-soaking might not be required, if a moist wound
environment is present prior to treatment. (10/10)
 Pre-soaking is not recommended in an emergency indi-
cation for the prevention of burn induced compartment
syndrome. (10/10)
 An additional mechanical cleaning step can be performed
at the end of the pre-soaking phase .(10/10)
The participants agree (10/10) that anti-infective agents are
not superior for pre-soaking, compared to saline or ringer
solution. Solutions that are applied for pre-soaking by the
participants: chlorhexidine 0.5% based solution (3/10), physi-
ologic saline solution (1/10), sulfonamide based solution (1/10),
Flamigel
1
(1/10) or polyhexanide based solutions (5/10). Gel
based covers prior to treatment keep the wound bed moist, and
thus an additional pre-soaking phase is not necessary.
If enzymatic debridement is applied for early eschar
removal to prevent surgical escharotomy due to compartment
syndrome, immediate application without pre-soaking should
be performed in order to have a timely interaction of the
enzymes.
Late burns with a dry eschar (>72h from injury) require
additional preparation by mechanical removal of superficial
layers followed by prolonged pre-soaking up to 12h in order to
improve the efficacy of debridement.
3.4.3. Product application
 The enzymes should be applied for 4h. (10/10)
 2g/1% BSA should be applied in adult patients in order to
achieve an active agent layer of approximately 1.5–3mm
thickness. (10/10)
 Even distribution of the enzymes over the entire wound
area is required. (10/10)
A reduction of exposure time to the enzymes is possible, but
should be performed according to personal experience in order
to maintain efficacy. A shorter exposure time may be possible
when treating more superficial burns. 2/10 participants have
experienced sufficient efficacy of enzymatic debridement with
a minimum of 2h application. 2/10 participants have experi-
enced an efficient and safe treatment when keeping the
enzymes on for longer than 4h (mainly due to logistical
reasons) without any side-effects. The enzymes do not
undergo spontaneous inactivation after 4h. In general, after
4h there is no eschar left, which is the basis for the above-
mentioned recommendation.
3.4.4. Initial phase after treatment (also known as “post-
soaking phase”)
 The application of a moist dressing for at least 2h is
recommended. (10/10)
 Prolonged application up to 18h can improve the results of
enzymatic debridement. (10/10)
7/10 centers practice a prolonged initial post-treatment
-phase up to 12h, in order to remove the remnants in the next
morning (due to logistic reasons). Prolonged post-soaking
improves the removal of enzymes, gel and dissolved eschar
remnants. The participants agree (10/10) that anti-infective
agents are not predominantly necessary after treatment,
compared to saline or ringer solution. In general, most
participants apply the same solutions for the after -phase as
in the pre-soaking phase.
3.4.5. Debridement dressing
 Enzymatic debridement benefits from sterile occlusive
dressings with minimal dead space. (10/10)
 The dressing during enzymatic debridement includes (10/
10):
 An adhesive local barrier (e.g. paraffin/vaseline gauze or
ointment, or stoma paste) should be applied 2–3cm
outside the treated area in order to prevent leakage of the
active agent
 Occlusive film
 Bulky, protective dressing
3.4.6. Time to complete removal of eschar
 Complete eschar removal should be achieved within 7 days
of injury. (10/10)
Application of enzymatic debridement is recommended
within 72h of injury. In case of incomplete early eschar
removal by enzymatic debridement, additional eschar remov-
al by hydrosurgery or standard of care should be performed in
order to complete eschar removal within the first 7 days after
burn injury. This is necessary in order to reduce risk of
colonization and infection, which has been also reported in
literature [1,2,24,25].
3.4.7. Re-application of enzymes
 Re-application of enzymatic debridement after initial
failure is currently not recommended. (10/10)
Re-application of the enzymes has been performed by 4/
10 centers (single additional application), as a personal
strategy based on the current off-label use. The participants
agree that a re-application is not recommended. Failure of the
initial application may be due to individual patient/burn- or
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user-based, or to date unknown factors of which at least some
must be addressed prior to re-application.
3.4.8. Wound bed assessment after Enzymatic Debridement
 Wound assessment should be performed within 2h after
treatment. (10/10)
 Post- treatment wound bed color and bleeding patterns
play a key role in diagnosing the depth of the wound. (9/10)
 A uniform red or pink post Enzymatic Debridement wound
bed after treatment represents high chances for sponta-
neous healing. (10/10)
 A uniform white wound bed with pin-point punctate
bleeding has good chances for spontaneous healing with
acceptable results. (10/10)
 A wound bed with large diameter red circles or oval
patterns is associated with prolonged healing and skin
grafting should be considered in these wounds. (10/10)
 Exposed fat post Enzymatic Debridement is a clear
indication for skin grafting. (10/10)
The larger the diameter of the circular patterns (skin
appendages/fat) inthedermis, thedeeperthedermis isaffected.
Exposed fatafter treatment isa clearindication for skin grafting.
Woundassessment for bleeding pattern should beperformed at
a standardized point of time. While 2/10 participants regard this
as optimal 2h after treatment phase, 8/10 prefer evaluation
straight after finishing enzymatic debridement. It is recom-
mended to reassess the wound depth after removal of the post
soaking as sometimes bleeding immediately after removal of
Enzymatic Debridement may interfere with accurate
assessment.
3.5. Post-interventional care of wounds after enzymatic
debridement — wound management
Care after treatment is essential to provide optimal outcome of
the technique, reduce instable scarring and keep the proce-
dure as minimally-invasive as possible by reducing the
number of unnecessary secondary procedures.
3.5.1. Enzymes removal
 Debris and the residues of the enzymes and dissolved
dermis should be removed by scraping. (10/10)
3.5.2. Wound bed preparation after Enzymatic Debridement
 After enzymatic debridement, it is necessary to keep a
moist environment to avoid desiccation. (10/10)
3.5.3. Pseudo-eschar: assessment and how to deal with it
 Pseudo-eschar is a specific layer sticking to the wound that
may develop several days after treatment. (10/10)
 If an occlusive layer remains >14 days, surgical re-
debridement should be taken into consideration. (10/10)
Pseudo-eschar results from exudate and the degradation of
proteins as well as residues from topical agents and
temporarily sticks to the surface. Spontaneous peeling of
areas of the pseudo-eschar revealing epithelial islands
underneath is a sign to not re-debride after 14 days. In general,
pseudo-eschar is not an obstacle for spontaneous healing.
3.5.4. Role of granulation tissue
 Granulation tissue may develop in prolonged spontaneous
healing after Enzymatic Debridement starting at day 14.
(10/10)
 Hypergranulation is a sign of insufficient reepithelization.
(10/10)
 Granulation tissue requires topical treatment followed by
secondary healing or surgical treatment. (10/10)
 Topical steroids can be recommended to avoid hyper-
granulation. (10/10)
In general, granulation tissue is expected to appear in areas
of remaining very deep viable dermis sometime between 14–21
days after enzymatic debridement, where prolonged sponta-
neous wound healing is to be expected. In order to support
epithelization, several days of topical steroids treatment are
recommended in order to suppress granulation tissue as early
as possible after its appearance.
The participants recommend temporary dressings and
membranes to reduce the frequency of dressing changes,
which provides comfort and reduces pain. In addition, it
provides an optimal wound bed for the re-epithelization
phase.
In case of clear punctate bleeding (assessment of an
efficient debridement), temporary, hydrolysable membranes,
allografts and xenografts for 10–14 days may reduce the
frequency of dressing change and are suitable for preventing
desiccation supporting spontaneous epithelization.
3.6. Skin grafting after enzymatic debridement
Skin grafting may become necessary in some deep-dermal
(grade 2b) burns with prolonged healing to reduce instable
scarring. It is always necessary in full thickness burns after
enzymatic debridement.
Enzymatic debridement reduces the number and surface of
skin grafting procedures. (10/10)
3.6.1. Timing
 Enzymatic debridement should be regarded as a debride-
ment tool, and autologous skin grafting or other recon-
structive procedures including application of dermal
substitutes or flaps should be performed if stable healing
cannot be expected. (10/10)
 In case of full thickness burns after treatment, autologous
skin grafting should be delayed for at least 2 days. (10/10)
 Enzymatic debridement may allow good results even after
a prolonged healing time. (10/10)
 Autologous skin grafting is advisable at latest after 21 days
if there is no progress in epithelization. (7/10)
 Delayed healing might result in unstable scarring and
insufficient functional and aesthetic results. (10/10)
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If static wound dynamics are evident and epithelization
does not proceed despite optimal topical treatment, re-
debridement and autologous skin grafting have to be taken
into consideration. There is a significant learning curve to
assess timing and the track of prolonged spontaneous healing.
There was an ongoing controversy regarding the appropriate
time point to select patients for re-debridement and skin
grafting. The participants agree that in case of prolonged
healing without surgery, a watchful observation with frequent
inspections is necessary not to miss the right moment of
insufficient delayed healing. The combined experience of the
panelists is that a delay of skin grafting for at least 2 days after
enzymatic debridement is necessary in order to get a basic
wound bed integrity to improve take rate. Superficial wound
bed preparation in order to achieve pinpoint bleeding is
necessary prior to skin grafting.
3.6.2. Use of dermal replacement matrices
 When enzymatic debridement is applied in full-thickness
burns, dermal replacement matrices may be used. (10/10)
3.7. Scar prevention
Scar treatment (Massage, ointment, compression garments,
silicon, etc.) should immediately start after healing. (10/10)
3.8. Blood loss
 Enzymatic debridement reduces blood loss compared to
standard of care. (10/10)
 Enzymatic debridement might induce relevant blood loss
in patients with coagulopathy or therapeutic anticoagu-
lation. (9/10)
With reference to the systematic review, the participants
agree to the potential of enzymatic debridement to reduce
blood loss compared to standard of care. However if coagul-
opathy occurs or anticoagulative treatment is installed, there
is a risk of increased blood loss and cautions should be taken.
Monitoring of hemoglobin is mandatory even if limited blood
loss is expected.
3.9. Training strategies and learning curve
Training strategies are essential in order to reduce the number
of preventable pitfalls and build up a team to implement the
use of enzymatic debridement.
 Enzymatic debridement benefits from standardized pro-
tocols and significant experience in the field of burn care
and surgery. (10/10)
 Enzymatic debridement requires clear communication and
multi-professional training. (10/10)
 Logistic requirements of enzymatic debridement have to be
considered prior to implementation. (10/10)
The participants agree that the application of enzymatic
debridement itself is a simple procedure that can be performed
after minimal training, but the pre and post treatment
assessment and treatment consequences are more complex,
requiring experienced burn care teams and training in order to
shorten their learning curves. Training programs and center
specific standard of care documents should include prepara-
tion for enzymatic debridement and arrangement of logistics
including multidisciplinary cooperation, wound bed assess-
ment and treatment strategies, dressings after treatment
(based on local supply) and indications for skin grafting after
treatment.
4. Discussion
The provided consensus statements aim to serve as user-
orientated recommendations for enzymatic debridement
beyond the current available evidence in the literature. Peer-
reviewed publications on enzymatic debridement were in-
cluded to support the statements whenever appropriate, but
this consensus document is not aimed to serve as a systematic
review on enzymatic debridement. Although there is an
increasing amount of evidence available on enzymatic
debridement in burns [4,9–11], the technique per se is relatively
new for widespread clinical application and requires a special
strategy for successful implementation including technical
training and wound bed evaluation compared to the standard
of care. The consensus panel included experts from Europe
with a combined experience of >500 patients treated with
enzymatic debridement. The aim of this consensus paper is to
prevent users from unnecessary pitfalls.
To start with, extremity burns (upper and lower extremity)
followed by face burns are regarded as beneficial burnt surface
areas in order to have an improved learning curve. In addition,
for hands and face, Enzymatic Debridement is regarded to be
superior to hydrosurgery or standard of care, which is reflected
in the current literature [8,11]. Compared to the SOC, it is
significantly important to provide a highly moist eschar prior
to enzymes application, either by postburn application of gel
based topical agents or a defined pre-soaking phase. Both
before and after treatment, wound bed evaluation are key
steps in achieving successful post-burn results, and require
experience and training. An early application of enzymatic
debridement in circumferential burns may prevent the need
for surgical escharotomy, but is not an effective tool for
decompression of deeper compartments in a combined
mechanism of injury such as electrocution, crush-burn or
explosion. The issues on enzymatic debridement achieving
only 70% of consensus are indication and timing of skin
grafting after partial thickness burns including the handling
and interpretation of pseudo-eschar, the use of enzymatic
debridement in mass casualties and the application of regional
anesthesia for pain management. In view of timing of
autologous skin grafting, it is regarded necessary to prevent
instable scarring when prolonged secondary healing seems to
occur. The best affordable consensus (7/10) for a general
recommendation included autologous skin grafting to be
performed at latest after 21 days if there is no progress seen in
epithelialization, while some panelists even report on stable
epithelialization >21 days after burn. Addressing the use of
enzymatic debridement in mass-casualties, all participants
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agreed about the ability of enzymatic debridement to debride a
large amount of burn patients within a small timeframe, i.e.
increase surge capacity in a mass casualty incident. An
unanimous recommendation for the use of enzymatic de-
bridement in mass casualty events could not be reached (7/10)
due to concerns of 3 panelists of creating a situation where
many patients with open wounds requiring timely skin
grafting exist simultaneously. However, the alternative of
delayed eschar removal is detrimental, and the concerns
expressed may be alleviated by temporary coverage, e.g. use of
allo- or xenograft or other temporary covers. Concerns in the
application of regional anesthesia in Enzymatic Debridement
(7/10) mostly derive from experience of some centers with
complications of regional anesthesia.
Relevant areas of future research have been identified by
the expert panel and include reduction of the inflammatory
local response, optimization of perfusion and drainage due to
reduced posttraumatic edema, dermal layer preservation,
patient satisfaction perspective, role in mass casualty and
systemic response after enzymatic debridement.
We feel the need to state the limitations of a consensus
panel with potential bias from individual experience and
potential influence on other panelists during face-to-face
discussions.
5. Conclusion
To the best of our knowledge, this is the first document
summarizing user-oriented guidelines for enzymatic debride-
ment, providing application recommendations and strategies
in order to optimize the learning curve of this innovative
technique. According to the Willy and Stellar scheme, all
statements could be included. The degree of consensus is
remarkably high, with a total consensus in 88.2% of state-
ments, with the lowest degree of 70% consensus in only 3 out of
68 statements.
The statements obtained by the consensus panel provide a
minimal set of guidelines available for the use of enzymatic
debridement, and should be understood as such, in addition to
the available evidence in the current literature. We believe that
future readjustment and fine-tuning of these recommenda-
tions should be performed as further knowledge and evidence
becomes available, which we expect will happen in the course
of the next years.
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